カテゴリ： GlobalData, アメリカ, 企業調査

Aerie Pharmaceuticals Inc (AERI)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Aerie Pharmaceuticals Inc (AERI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9810
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：66
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Aerie Pharmaceuticals Inc (Aerie) is a pharmaceutical company that discovers, develops and commercializes therapies for the treatment of patients with glaucoma and other diseases of the eye. The company’s product candidates comprise rhopressa, a once-daily eye drop which is used for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; and roclatan, a fixed-dose combination of rhopressa and latanoprost. Aerie works in partnership with other pharma companies and universities for drug discovery technologies. The company has presence in the US and Ireland. Aerie is headquartered in Irvine, California, the US.

Aerie Pharmaceuticals Inc (AERI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aerie Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Aerie Pharma Acquires Rights of PRINT Technology and Other Assets from Envisia Therapeutics 12
Venture Financing 13
Aerie Pharma Raises Additional USD12 Million in Venture Financing 13
Aerie Pharma Raises US$3 Million In Venture Financing 14
Partnerships 15
ViSci Enters Into Option Agreement with Novaer to License Eye-D Technology 15
Aerie Pharma Enters into R&D Agreement with Royal DSM 16
Licensing Agreements 17
Aerie Pharma Expands Licensing Agreement with DSM Biomedical 17
Aerie Pharma Enters into Licensing Agreement with Ramot at Tel Aviv University 18
Aerie Pharma Enters into Licensing Agreement with GrayBug 19
Equity Offering 20
Aerie Pharma Raises USD74.3 Million in Public Offering of Shares 20
Aerie Pharma Raises USD75 Million in Public Offering of Shares 22
Aerie Pharma Raises USD75 Million in Public Offering of Shares 24
Aerie Pharma Plans Public Offering of Shares for up to USD50 Million 26
Aerie Pharma Completes IPO For US$77.3 Million 27
Debt Offering 29
Aerie Pharma Raises USD125 Million in Private Placement of 1.75% Notes Due 2021 29
Aerie Pharmaceuticals Inc – Key Competitors 31
Aerie Pharmaceuticals Inc – Key Employees 32
Aerie Pharmaceuticals Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Strategy And Business Planning 35
Oct 23, 2018: Aerie Pharmaceuticals establishes GMP PRINT production facility in an expanded global headquarters 35
Financial Announcements 36
Nov 06, 2018: Aerie Pharmaceuticals reports third quarter 2018 financial results and provides business update 36
Aug 08, 2018: Aerie Pharmaceuticals reports second quarter 2018 financial results and provides business update 38
May 08, 2018: Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update 39
Feb 28, 2018: Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update and 2018 Guidance 40
Nov 08, 2017: Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update 42
Aug 01, 2017: Aerie Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 43
May 02, 2017: Aerie Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update 44
Mar 07, 2017: Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 45
Corporate Communications 46
Sep 12, 2018: Aerie Pharmaceuticals names David W. Gryska as Board Director 46
Dec 04, 2017: Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region 47
Aug 28, 2017: Aerie Pharmaceuticals Announces Appointment of Deanne Melloy as Vice President of Marketing and Norbert Lowe as Regional Sales Director 48
Apr 24, 2017: Aerie Pharmaceuticals Announces Appointment of Raymond S. Wysmierski as Director of Compliance 49
Apr 10, 2017: Aerie Pharmaceuticals Announces Expansion of Commercialization Team 50
Product News 51
12/18/2017: Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension 51
08/15/2018: Aerie Pharmaceuticals Reports Topline Result from Rhopressa Mechanism of Action Study 52
05/03/2017: Envisia Therapeutics Announces New Data On ENV1105 At ASCRS 2017 Annual Meeting 53
04/30/2018: Aerie Pharmaceuticals Announces U.S. Launch of Rhopressa (netarsudil ophthalmic solution) 0.02% 54
Feb 21, 2018: New glaucoma drugs yield large, lasting reductions in intraocular pressure 55
Product Approvals 56
Oct 13, 2017: Aerie Pharmaceuticals Announces FDA Advisory Committee Vote in Favor of Rhopressa (netarsudil ophthalmic solution) 0.02% 56
Sep 20, 2017: Aerie Pharmaceuticals Announces FDA Advisory Committee Meeting for Rhopressa (netarsudil ophthalmic solution) 0.02% 57
Aug 08, 2017: Aerie Pharmaceuticals Comments on Notification from Contract Manufacturer 58
May 15, 2017: Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa (netarsudil ophthalmic solution) 0.02% 59
Mar 01, 2017: Aerie Pharmaceuticals Announces Resubmission of NDA for Rhopressa (netarsudil ophthalmic solution) 0.02% 60
Clinical Trials 61
Oct 09, 2018: Aerie Pharmaceuticals Announces Drug Application for Regulatory Approval Accepted for Review in Europe 61
Nov 16, 2017: Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan 62
Apr 12, 2017: Aerie Pharmaceuticals Reports Positive Rocket 4 Six-Month Topline Safety and Efficacy Results for RhopressaTM (netarsudil ophthalmic solution) 0.02% 63
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66

List of Tables
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aerie Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aerie Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aerie Pharma Acquires Rights of PRINT Technology and Other Assets from Envisia Therapeutics 12
Aerie Pharma Raises Additional USD12 Million in Venture Financing 13
Aerie Pharma Raises US$3 Million In Venture Financing 14
ViSci Enters Into Option Agreement with Novaer to License Eye-D Technology 15
Aerie Pharma Enters into R&D Agreement with Royal DSM 16
Aerie Pharma Expands Licensing Agreement with DSM Biomedical 17
Aerie Pharma Enters into Licensing Agreement with Ramot at Tel Aviv University 18
Aerie Pharma Enters into Licensing Agreement with GrayBug 19
Aerie Pharma Raises USD74.3 Million in Public Offering of Shares 20
Aerie Pharma Raises USD75 Million in Public Offering of Shares 22
Aerie Pharma Raises USD75 Million in Public Offering of Shares 24
Aerie Pharma Plans Public Offering of Shares for up to USD50 Million 26
Aerie Pharma Completes IPO For US$77.3 Million 27
Aerie Pharma Raises USD125 Million in Private Placement of 1.75% Notes Due 2021 29
Aerie Pharmaceuticals Inc, Key Competitors 31
Aerie Pharmaceuticals Inc, Key Employees 32
Aerie Pharmaceuticals Inc, Other Locations 34
Aerie Pharmaceuticals Inc, Subsidiaries 34

List of Figures
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aerie Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Aerie Pharmaceuticals Inc (AERI)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Catalyst Paper Corporation：企業の戦略的SWOT分析
    Catalyst Paper Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Buckeye Partners, L.P.：企業の戦略・SWOT・財務分析
    Buckeye Partners, L.P. - Strategy, SWOT and Corporate Finance Report Summary Buckeye Partners, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Merck KGaA (MRK)：製薬・医療：M&Aディール及び事業提携情報
    Summary Merck KGaA (Merck), a subsidiary of E. Merck KG, is a pharmaceutical and chemical company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis, and infertility and over-the-counter products for colds and pain; and develops liquid crystal mixtures, O …
  • Inter Parfums SA：企業の戦略・SWOT・財務情報
    Inter Parfums SA - Strategy, SWOT and Corporate Finance Report Summary Inter Parfums SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Energy Absolute Public Co Ltd (EA)：電力：M&Aディール及び事業提携情報
    Summary Energy Absolute Public Co Ltd (Energy Absolute), formerly Suntech Palm Oil Ltd, is a renewable energy service provider that offers opportunities for networking, education and business creation. The company provides products such as biodiesel and glycerin. It offers services such as dry washi …
  • ATLAS Oil Co：石油・ガス：M&Aディール及び事業提携情報
    Summary ATLAS Oil Co (ATLAS) is an oil and gas company that offers fuel supply and logistic services. The company’s services comprise supply, renewable fuels, bulk fueling, fuel on demand, logistics, fixed price contracts, frac site fueling, emergency refuel, crude hauling, transloading and on-site …
  • HollyFrontier Corp (HFC)：企業の財務・戦略的SWOT分析
    HollyFrontier Corp (HFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Sharp HealthCare：企業の戦略的SWOT分析
    Sharp HealthCare - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Vision International People Group Public Limited：戦略・SWOT・企業財務分析
    Vision International People Group Public Limited - Strategy, SWOT and Corporate Finance Report Summary Vision International People Group Public Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, …
  • Veolia Environnement SA (VIE)：企業の財務・戦略的SWOT分析
    Veolia Environnement SA (VIE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Red River Valley Mutual Insurance Company：企業の戦略・SWOT・財務情報
    Red River Valley Mutual Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Red River Valley Mutual Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Coffee Republic Trading Ltd：企業の戦略・SWOT・財務分析
    Coffee Republic Trading Ltd - Strategy, SWOT and Corporate Finance Report Summary Coffee Republic Trading Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Cantel Medical Corp. (CMD)-医療機器分野：企業M&A・提携分析
    Summary Cantel Medical Corp. (Cantel) is a manufacturer and distributor of infection prevention and control products and services to the healthcare market. The company’s product portfolio includes water purification equipment, sterilants, disinfectants and cleaners, specialized medical device reproc …
  • Esab Holdings Ltd：企業の戦略・SWOT・財務分析
    Esab Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Esab Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • John B. Sanfilippo & Son, Inc.：企業の戦略・SWOT・財務情報
    John B. Sanfilippo & Son, Inc. - Strategy, SWOT and Corporate Finance Report Summary John B. Sanfilippo & Son, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Providence Service Corporation：戦略・SWOT・企業財務分析
    Providence Service Corporation - Strategy, SWOT and Corporate Finance Report Summary Providence Service Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Cabela’S Inc
    Cabela'S Inc - Strategy, SWOT and Corporate Finance Report Summary Cabela'S Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • KACO new energy GmbH：企業の戦略的SWOT分析
    KACO new energy GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Oncolys BioPharma Inc (4588)-製薬・医療分野：企業M&A・提携分析
    Summary Oncolys BioPharma Inc (Oncolys) is a biotechnology company that discovers, and develops treatments for cancer and infectious diseases. The company imports and exports oncolytic viruses, drugs and medicines, and tumor diagnostic agents. Its pharmaceutical pipeline products include OBP-301, OB …
  • Sensorion SA (ALSEN)：企業の財務・戦略的SWOT分析
    Summary Sensorion SA (Sensorion) is a biopharmaceutical company that develops therapies. The company provides treatments for vestibular and cochlear pathologies. It develops drug candidates through its technology platform for the treatment of various therapeutic areas including vestibular neuritis, …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆